Minerva suffers another CNS defeat; Eli Lilly wins OK for tau-based Alzheimer's diagnostic
→ Months after a depressing end to Minerva Neurosciences‘ quest to develop a depression drug, the Waltham, Massachusetts-based drug developer unveiled more bad news as its lead experimental compound — roluperidone — failed to succeed in a late-stage schizophrenia study. The Achilles heel of many a CNS failure reared its ugly head again: the dreaded larger-than-life placebo effect. But company chief Rémy Luthringer isn’t throwing in the towel just yet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.